Free Trial
→ Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000” (From Colonial Metals) (Ad)

Cingulate Q1 2024 Earnings Report

Cingulate logo
$4.32 +0.10 (+2.25%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$0.60
Consensus EPS
-$2.20
Beat/Miss
Beat by +$1.60
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q1 2024
Date
5/8/2024
Time
N/A

Conference Call Resources

Cingulate Earnings Headlines

What happens in your brain when there’s a word ‘on the tip of the tongue’?
February 14, 2025 | msn.com
What happens in the brain when there's a word 'on the tip of the tongue'?
February 13, 2025 | msn.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Cingulate CEO cleared of charges, retains board confidence
February 3, 2025 | msn.com
Cingulate price target adjusted to $20 from $8 at H.C. Wainwright
January 30, 2025 | markets.businessinsider.com
Cingulate stock price target raised to $20 at H.C. Wainwright
January 30, 2025 | msn.com
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles